期刊文献+

紫杉醇联合替吉奥胶囊治疗晚期胃癌疗效观察 被引量:11

原文传递
导出
摘要 目的观察紫杉醇联合替吉奥胶囊治疗晚期胃癌的近期疗效和安全性。方法经手术或活检组织病理确诊49例晚期胃癌患者随机分为2组,对照组(24例)给予紫杉醇+亚叶酸钙+氟尿嘧啶方案化疗,观察组(25例)给予紫杉醇联合替吉奥胶囊方案化疗,2组均21d为1个周期;化疗2个周期进行1次疗效评定,以化疗结束时疗效作为最终疗效;观察并比较2组治疗有效率和不良反应。结果观察组完全缓解2例,部分缓解12例,稳定8例,进展3例,总有效率56.0%;对照组完全缓解1例,部分缓解5例,稳定15例,进展3例,总有效率25.0%,2组比较差异有统计学意义(χ2=4.871,P=0.027);观察组和对照组Ⅰ~Ⅱ度恶心呕吐发生率比较差异有统计学意义(χ2=7.351,P=0.007),2组骨髓抑制、贫血、腹泻或便秘、脱发、口腔炎、肝功能损害、肾功能损害发生率比较差异无统计学意义(P>0.05)。结论紫杉醇联合替吉奥胶囊治疗晚期胃癌疗效满意,不良反应轻。
出处 《中华实用诊断与治疗杂志》 2012年第12期1214-1216,共3页 Journal of Chinese Practical Diagnosis and Therapy
  • 相关文献

参考文献9

二级参考文献31

共引文献12

同被引文献82

  • 1孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:568-569.
  • 2Shiono S,Harada M,Abiko M,et al.A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival[J].Gan To Kagaku Ryoho,2014,41:757-759.
  • 3Shien T,Iwata H,Fukutomi T,et al.Tamoxifen plus tegafur-uracil(TUFT)versus tamoxifen plus Adriamycin(doxorubicin)and cyclophosphamide(ACT)as adjuvant therapy to treat nodepositive premenopausal breast cancer(Pre MBC):results of Japan Clinical Oncology Group Study 9404[J].Cancer Chemother Pharmacol,2014,74:603-609.
  • 4Yamamiya I,Yoshisue K,Ishii Y,et al.Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity[J].Drug Metab Dispos,2014,42:1485-1492.
  • 5Shimada Y,Hamaguchi T,Mizusawa J,et al.Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection:final results of JCOG0205[J].Eur J Cancer,2014,50:2231-2240.
  • 6Tsuburaya A,Yoshida K,Kobayashi M,et al.Sequential paclitaxel followed by tegafur and uracil(UFT)or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer(SAMIT):a phase 3 factorial randomised controlled trial[J].Lancet Oncol,2014,15:886-893.
  • 7Zhang Z, Mei L, Feng SS. Paclitaxel drug delivery systems[J]. Expert Opin Drug Del, 2013,10(3) :325-340.
  • 8Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis[J]. Cancer Treat Rev, 2012,38(6) : 613-617.
  • 9Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer pharmacology and molecular mechanisms group and new drug development group[J]. Clin Cancer Res, 2007,13(21):6410-6418.
  • 10Joerger M, Kraff S, Huitema AD, et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring [J]. Clin Pharmacokinet, 2012,51 (9):607-617.

引证文献11

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部